English

Navamedic presents Q4 2005 results at Felix at 08:00 on Friday 17 February

Report this content
Navamedic ASA would like to invite to a presentation of the company's Q4 2005 results on 17 February 2006. The presentation will take place at Felix Conference Centre at Aker Brygge, Bryggetorget 3, 0114 Oslo, and will start at 08:00 a.m. Participants are requested to register at firma@navamedic.com or by calling +47 67 11 25 40.
For further information, please contact:


CEO Øyvind S. Brekke, Navamedic
E-mail: oyvind.brekke@navamedic.com
Office: +47 67 11 25 40, Mobile: +47 91 19 81 64


CFO Jon W. Ringvold, Navamedic
E-mail: jon.ringvold@navamedic.com
Office: +47 67 11 25 44 Mobile: +47 99 15 85 34


 
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl based medicines. Glucosamine is a generic active ingredient against osteoarthritis with a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world's population. Navamedic aims to become a leading company in the glucosamine industry by capitalising on proprietary production technology. The company's products will be sold through a network of sales, marketing and distribution partners in each country. Navamedic's product Glucomed® was approved as a medicine against osteoarthritis by the Swedish Medical Products Agency in August 2005. The Company aims to apply for a listing on the Oslo Stock Exchange during Q1 2006.

Subscribe